Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer

Baculi RH, Suki S, Nisbett J, Leeds N, Groves M (2001) Meningeal carcinomatosis from breast carcinoma responsive to trastuzumab. J Clin Oncol 19: 3297–3298

Bendell JC, Domchek SM, Burnstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97: 2972–2977

Brufsky AM, Cleary D, Fuchs C, Lebish J, Baar J, Evans T, Lembersky B, Belani CP (2003) First-line chemotherapy for metastatic breast cancer (MBC) with docetaxel (T), carboplatin (C), and trastuzumab (H) (TCH): a phase II trial. Proc Am Soc Clin Oncol 22: A71

Clark GM, Sledge Jr GW, Osborne CK, McGuire WL (1987) Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5: 55–61

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Frenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanised anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648

Crivellari D, Pagani O, Veronesi A, Lombardi D, Nole F, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A (2001) High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12: 353–356

DiStefano A, Yap HY, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44: 1913–1918

Emi Y, Kitamura K, Shikada Y, Kakeji Y, Takahshi I, Tsutsui S (2002) Metastatic breast cancer with HER2/neu-positive cells tends to have a morbid prognosis. Surgery 131: S217–S221

Fournier M, Risio M, Posnak CV, Seideman A (2002) HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology 16: 1340–1358

Gerosa M, Nicolato A, Foroni R, Zanotti B, Tomazzoli L, Miscusi M, Alessandrini F, Bricolo A (2002) Gamma knife radiosurgery for brain metastases: a primary therapeutic option. J Neurosurg 97 (Suppl 5): 515–524

Heinrich B, Brudler O, Siekiera W, Raab G, Heinemann V (2003) Development of brain metastases in metastatic breast cancer (MBC) responding to treatment with trasuzumab. Proc Am Soc Clin Oncol 22: A147

Maki DD, Grossman RI (2000) Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. Am J Neuroradiol 21: 1064–1066

Miller KD, Weathers T, Hanley LG, Timmerman R, Dickler M, Shen J, Sledge Jr GW (2003) Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14: 1072–1077

Neve RM, Lane HA, Haynes NE (2001) The role of overexpressed HER2 in transformation. Ann Oncol 12 (Suppl 1): S9–S13

Pestalozzi BH, Brignoli S (2000) Trastuzumab in CSF. J Clin Oncol 18: 2350–2351

Pottgen C, Stuschke M (2001) The role of prophylactic cranial irradiation in the treatment of lung cancer. Lung Cancer 33: S153–S158

Rosner D, Nemoto T, Lane WW (1986) Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58: 832–839

Rubin I, Yarden Y (2001) The basic biology of HER2. Ann Oncol 12: S3–S8

Seideman AD, Fournier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Boynahan M, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Hudis CA (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587–2595

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

Stewart JF, King RJ, Sexton SA, Millis RR, Rubens RD, Hayward JL (1981) Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17: 449–453

Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastases from breast carcinoma. Cancer 52: 2349–2354

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726

Wardley AM, Danson S, Clayton AJ, Clemmons M, Burt P, Stewart A, Waine S, Wilkinson P, Welch R, Magee B, Howell A (2002) High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer centre. Proc Am Soc Clin Oncol 21: A241